avid_creative Investment Overview Merck & Co., Inc. (NYSE:MRK) will announce its Q1 2024 earnings next Thursday, April 25. Analysts’ consensus opinion is that earnings per share will be in the region of $1.99 on a normalized basis, or $1.87 on a GAAP basis, on revenues of ~$15.2bn. Big pharma is generally regarded as a strong…
Sundry Photography One of the biggest pharmaceutical stocks by market capitalization, Merck & Co., Inc. (NYSE:MRK) has had a good first quarter at the stock markets in 2024. Its price is up by over 20% after a forgettable 2023 that saw it end the year essentially flat, supported by approvals for its treatments as well…
Anne Czichos/iStock Editorial via Getty Images Introduction Merck KGaA (OTCPK:MKGAF) is the “original” of the two Merck companies. Established as a pharmacy in 1668 in Darmstadt, the company has since grown to be one of Europe’s dominant companies in the healthcare and life sciences industry with exposure to the semiconductor space. The company had a…
Diy13 Introduction I try to follow a few rules when I invest in dividend (growth) stocks. This includes staying away from car manufacturers, consumer stocks with severe competition risks, and healthcare companies with complex pipelines and elevated patent risks. So far, I have broken the healthcare rule a few times, especially when I continued buying…
Merck & Co., Inc. (NYSE:MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference January 4, 2024 ET Company Participants Peter Dannenbaum – Head, IR Rob Davis – CEO Conference Call Participants Chris Shibutani – Goldman Sachs Chris Shibutani I suspect that people are going to be strolling in, but I don’t like to penalize people who are…
JuSun It’s almost the end of the year, and is a good time to re-evaluate one’s portfolio in terms of potential winners and losers next year. With the market chasing growth stocks to nosebleed valuations, I believe better opportunities can be found to similar moat-worthy enterprises that are trading at far more reasonable valuations with…
Fischerrx6 Introduction As we head into the last trading days of 2023, I wanted to cover a stock I haven’t discussed before on Seeking Alpha. That company is Merck & Co. (NYSE:MRK), a drug manufacturer with a market cap of more than $270 billion. The reason why I never covered MRK is because I thought…
Merck & Co., Inc. (NYSE:MRK) 6th Annual Evercore ISI HealthCONx Conference Transcript November 30, 2023 1:20 PM ET Executives Dr. Eliav Barr – Senior Vice President, Head, Global Clinical Development and CMO Peter Dannenbaum – Vice President, Investor Relations Analysts Umer Raffat – Evercore Umer Raffat Thank you. Listen, thank you guys for being here….
With one of the best known brands in the world, Nike will increase its dividend growth streak to 23 years with its next boost in the second half of November. Thank you for your assistant This is the latest in my series of articles where I provide predictions of annual dividend increases for long-term dividend…
MoMo Productions Dear readers/followers, I last wrote about Evotec (NASDAQ:EVO) back in April of this year, after a reader asked me to take a look at German company Evotec, which also has a dual listing on NASDAQ under the symbol EVO. The question was about undervaluation. Despite going in at a “BUY” rating, I myself…
franckreporter Exscientia investment summary In the last coverage on Exscientia plc (NASDAQ:EXAI), I noted the following points: “Just as profitability and return on invested capital are heralded as the economic moats investors are in search for, innovation, and speed of innovation are equally as attractive. Within the field of drug discovery and development, persistent challenges…
Merck & Co., Inc. (NYSE:MRK) Citi 18th Annual BioPharma Conference September 6, 2023 1:50 PM ET Company Participants Marjorie Green – SVP and Head of Late Stage Oncology, Global Clinical Development Conference Call Participants Andrew Baum – Citi Andrew Baum So delighted to introduce our next speaker, Dr. Marjorie Green at Merck, who heads Oncology…
Erik S. Lesser In the dynamic world of pharmaceuticals, Merck & Co., Inc. (NYSE:MRK) has consistently emerged as a formidable player, showcasing resilience and innovation. While recent stock market trends show a slight decline in stock price, a more comprehensive view reveals Merck’s impressive performance compared to major equity indexes. At the heart of this…